WINTON GROUP Ltd Takes $4.82 Million Position in LivaNova PLC $LIVN

Key Points

• WINTON GROUP Ltd acquired 58,661 LivaNova shares worth approximately $4.82 million, while institutional investors collectively owned 97.64% of the company.
• Analysts maintain a generally positive outlook, with a consensus “Moderate Buy” rating and an average price target of $84.12; Needham and KeyCorp recently raised their targets to $93 and $92, respectively.
• LivaNova exceeded quarterly expectations, reporting $1.26 in EPS and $390.59 million in revenue, with revenue up 10.8% year over year. Shares opened at $78.18, near their recent trading range high of $85.76.

WINTON GROUP Ltd purchased a new position in shares of LivaNova PLC (NASDAQ:LIVN - Free Report) in the second quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor purchased 58,661 shares of the company's stock, valued at approximately $4,824,000. WINTON GROUP Ltd owned 0.11% of LivaNova at the end of the most recent quarter.

A number of other hedge funds have also recently made changes to their positions in the stock. Maverick Capital Ltd. purchased a new position in shares of LivaNova during the first quarter worth $956,000. Renaissance Technologies LLC grew its position in shares of LivaNova by 15.7% during the first quarter. Renaissance Technologies LLC now owns 183,000 shares of the company's stock worth $11,631,000 after buying an additional 24,900 shares in the last quarter. Quantinno Capital Management LP increased its position in shares of LivaNova by 263.8% in the 1st quarter. Quantinno Capital Management LP now owns 55,562 shares of the company's stock valued at $3,532,000 after purchasing an additional 40,289 shares during the last quarter. Hsbc Holdings PLC increased its holdings in LivaNova by 260.6% in the fourth quarter. Hsbc Holdings PLC now owns 20,301 shares of the company's stock valued at $1,255,000 after buying an additional 14,671 shares during the last quarter. Finally, Rhenman & Partners Asset Management AB increased its holdings in shares of LivaNova by 258.5% in the 4th quarter. Rhenman & Partners Asset Management AB now owns 190,000 shares of the company's stock valued at $11,691,000 after acquiring an additional 137,000 shares during the last quarter. Hedge funds and other institutional investors own 97.64% of the company's stock.

Analysts Set New Price Targets

A number of research analysts recently commented on LIVN shares. Zacks Research downgraded shares of LivaNova from a "strong-buy" rating to a "hold" rating in a research report on Wednesday, August 19th. Needham & Company LLC boosted their target price on LivaNova from $81.00 to $93.00 and gave the company a "buy" rating in a report on Wednesday, August 5th. Stifel Nicolaus set a $85.00 price target on shares of LivaNova in a research note on Wednesday, August 5th. KeyCorp increased their price objective on LivaNova from $83.00 to $92.00 and gave the stock an "overweight" rating in a research report on Monday, June 22nd. Finally, Freedom Capital raised shares of LivaNova to a "hold" rating in a report on Tuesday, June 30th. Six research analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the company's stock. Based on data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average target price of $84.12.

Insider Transactions at LivaNova

In other LivaNova news, Director Brooke Story sold 2,300 shares of the company's stock in a transaction dated Friday, September 4th. The stock was sold at an average price of $81.42, for a total transaction of $187,266.00. Following the completion of the sale, the director directly owned 7,488 shares in the company, valued at $609,672.96. This represents a 23.50% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, Director Francesco Bianchi sold 1,650 shares of the stock in a transaction that occurred on Monday, August 31st. The stock was sold at an average price of $79.72, for a total transaction of $131,538.00. Following the sale, the director directly owned 7,934 shares of the company's stock, valued at approximately $632,498.48. This trade represents a 17.22% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. 0.35% of the stock is currently owned by insiders.

LivaNova Trading Down 1.0%

Shares of LivaNova stock opened at $78.18 on Friday. The business's fifty day moving average is $80.46 and its two-hundred day moving average is $73.29. The company has a quick ratio of 1.21, a current ratio of 1.45 and a debt-to-equity ratio of 0.22. LivaNova PLC has a fifty-two week low of $48.82 and a fifty-two week high of $85.76. The firm has a market cap of $4.31 billion, a PE ratio of 23.13 and a beta of 0.87.

LivaNova (NASDAQ:LIVN - Get Free Report) last posted its quarterly earnings results on Thursday, August 6th. The company reported $1.26 EPS for the quarter, beating the consensus estimate of $1.09 by $0.17. LivaNova had a return on equity of 16.35% and a net margin of 12.82%.The company had revenue of $390.59 million during the quarter, compared to analysts' expectations of $380.50 million. During the same quarter in the previous year, the business earned $1.05 EPS. The firm's revenue was up 10.8% on a year-over-year basis. Analysts anticipate that LivaNova PLC will post 3.77 earnings per share for the current year.

About LivaNova

LivaNova plc is a global medical technology company that develops and manufactures products and therapies for the cardiac surgery and neuromodulation markets. Headquartered in London, United Kingdom, and Houston, Texas, LivaNova serves hospitals, clinics and healthcare providers in more than 100 countries. The company's primary focus lies in advancing patient care through innovations in heart–lung bypass, cardiac preservation, circulatory support and neurostimulation therapies.

The Cardiac Surgery business unit offers a comprehensive portfolio of products used in cardiopulmonary bypass procedures, including oxygenators, heart–lung machines, arterial filters, cannulae and sutureless heart valves.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.